Sutinat 12.5mg Capsule

The human body shows undesired symptoms after taking the Sutinat 12.5mg capsule. Usually, they disappear with time as the body adjusts to the medicine. It is advised to consult your doctor if these symptoms become unmanageable. Some of the side effects of Sutinat capsule are mentioned below:

• Fatigue or weakness
• Nausea and vomiting
• Diarrhea
• Loss of appetite (decreased appetite)
• Hand-foot syndrome
• Skin discoloration, rash, dry skin, or itching
• High blood pressure
• Headache
• Hair loss
• Changes in taste
• Nosebleeds
• Mucositis (mouth sores)
  
• Heart failure or heart attack
• Elevated liver function tests or liver failure
• Proteinuria (protein in urine)
• Acute kidney injury
• Interstitial lung disease (lung inflammation)
• Pulmonary arterial hypertension
• Gastrointestinal perforation or fistula
• Haemorrhage (serious bleeding)
• Hypothyroidism (low thyroid function)
• Hypoglycemia (low blood sugar)
  

Sutinat 12.5mg capsule is a prescription-based anticancer medicine that should be administered orally. It is advised to take this capsule after consulting your healthcare expert. The capsules are to be taken orally at a specific time before or after food, swallowed whole, and dosed according to the type of cancer and the individual patient by a doctor. 

Sutinat 12.5mg capsule is an anticancer medicine that belongs to the class of tyrosine kinase inhibitors. This medication inhibits the tyrosine kinase, a surface protein that causes cancer cells to proliferate quickly. Additionally, it prevents the development of the blood vessels that provide tumor cells with oxygen. This capsule inhibits the development and spread of cancer cells in this way.

It is advised not to miss any scheduled dosage of Sutinat 12.5mg capsule. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. 

• It is advised to use effective birth control ways and avoid pregnancy during the treatment with Sutinat 12.5mg capsule.
• A person should avoid smoking while undergoing treatment with Sutinat 12.5mg capsule. Smoking may reduce the effectiveness of medicine.
• Skin becomes extremely sensitive after taking Sutinat capsule. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.
• Swelling of hands and lips and weight gain are some of the side effects observed after taking Sutinat 12.5mg capsule. To reduce them, the doctor may suggest some medication.
• It is advised to avoid taking analgesics/antacids (medicines used to neutralize the stomach acid) while taking Sutinat capsule, as it may reduce the effectiveness of the medicine.
• Keep your body hydrated, as diarrhea is one of the common side effects experienced after taking Sutinat 12.5mg capsule. Consult your doctor if it doesn't stop or if blood appears in your stools.
• Monitor your blood sugar & pressure, kidney & liver function (KFT & LFT), heart function, cholesterol level, and bone mineral density (BMD) at proper intervals after taking Sutinat.
• In case you notice symptoms like blurred vision, difficulty breathing, cough & fever, and diarrhea while taking Sutinat 12.5mg capsule, consult your doctor immediately before these symptoms become severe.
• If you experience any kind of symptoms after taking Sutinat 12.5mg capsule, like unexplained bruising or bleeding, sore throat, mouth ulcers, high temperature (fever), or other signs of infection, it is important to Inform your doctor as soon as possible.​
  

• Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database. (2024). Journal of Hepatology and Oncology. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest single-center retrospective analysis. (2023). Oncotarget / PMC open-access database - https://pmc.ncbi.nlm.nih.gov/articles/PMC7367626/
  
• Model‑based dose individualization of sunitinib in gastrointestinal stromal tumors. (2025). Clinical Cancer Research. - https://aacrjournals.org/clincancerres/article-abstract/26/17/4590/82846/Model-based-Dose-Individualization-of-Sunitinib-in
  
• Population pharmacokinetics of sunitinib and its active metabolite SU012662 in pediatric patients with gastrointestinal stromal tumors or other solid tumors. (2025). Pediatric Oncology Group / Clinical study - https://pmc.ncbi.nlm.nih.gov/articles/PMC8093178/?utm
  
• Randomized phase II trial evaluating the addition of low-dose, short-course sunitinib (12.5 mg) to docetaxel in advanced solid tumors. (2020). British Journal of Cancern - https://pubmed.ncbi.nlm.nih.gov/33203399/